The 2014 NCCN guidelines recommend FOLFIRINOX (leucovorin/5-fluorouracil plus oxaliplatin plus irinotecan) as a first-line treatment for patients with metastatic or locally advanced unresectable disease with good performance status. The NCCN recommended gemcitabine monotherapy for symptomatic patients with metastatic or locally advanced unresectable disease with poor performance status. Additional recommendations for metastatic disease were also added, including the GTX regimen (gemcitabine, docetaxel, and capecitabine) and combination therapy with gemcitabine and nab-paclitaxel.
For more on the treatment and management of pancreatic cancer, read here.
Medscape © 2014
Cite this: Fast Five Quiz: Do You Know the Risk Factors, Diagnostic Tests, and Treatment for Pancreatic Cancer? - Medscape - Oct 14, 2014.